Updated EMILIA Phase III Trial Results Confirm Increase in Overall Survival
Study: HPV Testing Can Predict Precancers For Nearly Two Decades Following Exam
Kyprolis Demonstrates Overall Response Following FDA Accelerated Approval
Trastuzumab Increases Risks Of Congestive Heart Failure
Breast Density Does Not Raise Breast Cancer Death Rates
Amgen Halts Phase III Trial Of Ganitumab Plus Gemcitabine
Spectral Mammography “Like Color vs. Black & White TV”
Study Reveals Racial Disparities In Surgical Prostate Care
2,000 Breast Cancer Recurrence Biomarker Candidates Discovered
NCI Approved CTEP Trials For the Month of August
FDA Approves Afinitor Tablets For Advanced Breast Cancer
Afinitor Suspension Approved For Rare Pediatric Brain Tumor
FDA Approves Xtandi For Late-Stage Castration-Resistant Prostate Cancer
Trending Stories
- In the Headlines: What’s in Trump’s draft budget?
- Trump administration seeks to slash NIH by roughly 40% as 27 institutes and centers are whittled down to eight
NCI to remain intact, but its finances are uncertain; FDA is spared big cuts - John Burklow replaced by Seana Cranston as NIH chief of staff
- DOD cancer research programs face 57% funding cut in year-long continuing resolution
Pancreatic, lung, kidney cancer research programs eliminated - In her own words: Rathmell reflects on her priorities and values—and encourages everyone to do the same
- NCI summarizes changes to the CCSG NOFO
